Aralez Pharmaceuticals Inc. (ARLZ) Stock Rating Reaffirmed by Chardan Capital
Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ)‘s stock had its “buy” rating reissued by stock analysts at Chardan Capital in a research note issued on Wednesday. They currently have a $10.00 price objective on the stock. Chardan Capital’s target price would suggest a potential upside of 107.90% from the stock’s current price.
Separately, Guggenheim reiterated a “buy” rating and issued a $12.00 price target on shares of Aralez Pharmaceuticals in a report on Monday, August 15th.
Aralez Pharmaceuticals (NASDAQ:ARLZ) opened at 4.81 on Wednesday. The stock has a 50 day moving average price of $5.26 and a 200-day moving average price of $4.21. Aralez Pharmaceuticals has a 1-year low of $3.10 and a 1-year high of $8.59. The stock’s market capitalization is $313.81 million.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last announced its quarterly earnings results on Tuesday, August 9th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by $0.08. The firm earned $12.60 million during the quarter, compared to analysts’ expectations of $9.70 million. Aralez Pharmaceuticals had a negative net margin of 224.35% and a negative return on equity of 73.21%. The company’s revenue for the quarter was up 142.3% compared to the same quarter last year. Equities research analysts expect that Aralez Pharmaceuticals will post ($1.06) EPS for the current year.
In other news, Director Robert Paul Harris sold 150,000 shares of the stock in a transaction dated Thursday, September 15th. The shares were sold at an average price of $5.82, for a total transaction of $873,000.00. Following the sale, the director now directly owns 669,094 shares of the company’s stock, valued at approximately $3,894,127.08. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 6.77% of the company’s stock.
Several large investors have recently bought and sold shares of ARLZ. GSA Capital Partners LLP raised its stake in Aralez Pharmaceuticals by 55.8% in the second quarter. GSA Capital Partners LLP now owns 92,395 shares of the company’s stock valued at $305,000 after buying an additional 33,100 shares during the last quarter. Drill Craig A raised its stake in Aralez Pharmaceuticals by 72.3% in the second quarter. Drill Craig A now owns 584,600 shares of the company’s stock valued at $1,929,000 after buying an additional 245,300 shares during the last quarter. California Public Employees Retirement System raised its stake in Aralez Pharmaceuticals by 10.0% in the second quarter. California Public Employees Retirement System now owns 105,867 shares of the company’s stock valued at $349,000 after buying an additional 9,667 shares during the last quarter. LMR Partners LLP purchased a new stake in Aralez Pharmaceuticals during the second quarter valued at about $145,000. Finally, FNY Managed Accounts LLC raised its stake in Aralez Pharmaceuticals by 73.3% in the second quarter. FNY Managed Accounts LLC now owns 52,000 shares of the company’s stock valued at $172,000 after buying an additional 22,000 shares during the last quarter. 49.63% of the stock is currently owned by institutional investors and hedge funds.
Aralez Pharmaceuticals Company Profile
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.